Different effects of aliskiren and losartan on fibrinolysis and insulin sensitivity in hypertensive patients with metabolic syndrome

Hormone and Metabolic Research

Volumn 42, Issue 12, 2010, Pages 892-896

  Fogari, R ^a   Zoppi, A ^a   Mugellini, A ^a   Lazzari, P ^a   Derosa, G ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

AT1R blockers; PAI 1 antigen; renin inhibition; tPA activity

Indexed keywords

ALISKIREN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOSARTAN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INFUSION; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MORNING DOSAGE; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; AMIDES; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; FEMALE; FIBRINOLYSIS; FUMARATES; HUMANS; HYPERTENSION; INSULIN; LOSARTAN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; YOUNG ADULT;

EID: 78249240095     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0030-1263123     Document Type: Article

References (33)

1. Juan Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997 78 656-660
2. Poli KA, Tofler GH, Larson MG, Evans JC, Sutherland PA, Lipinska I, Mittleman MA, Muller JE, DAgostino RB, Wilson PW, Levy D. Association of BP with fibrinolytic potential in the Framingham Offspring Population. Circulation 2000 101 264-269
3. Juhan-Vague I, Pyke SDM, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996 94 2057-2063
4. Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, Hallmans G. High plasminogen activator inhibitor (PAI-1) and tissue plasminogen activator (tPA) levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998 98 2241-2247
5. Juan Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia 1991 34 457-462
6. Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DE. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 1998 32 965-971
7. Vaughan DE. Angiotensin, fibrinolysis and vascular homeostasis. Am J Cardiol 2001 87 (Suppl.) 18C-24C
8. Wright RA, Flapan AD, Alberti KG, Ludlam CA, Fox KA. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol 1994 24 67-73
9. Sayer JW, Gutteridge C, Syndercombe-Court D, Wilkinson P, Timmis AD. Circadian activity of the endogenous fibrinolytic system in stable coronary artery disease: effects of beta-adrenoreceptor blockers and angiotensin converting enzyme inhibitors. J Am Coll Cardiol 1998 32 1962-1968
10. Sakata K, Shirotani M, Yoshida H, Urano T, Takada Y, Takada A. Differential effects of enalapril and nitrendipine on the fibrinolytic system in essential hypertension. Am Heart J 1999 137 1094-1099 (Pubitemid 30040734)
11. Fogari R, Zoppi A, Preti P, Fogari E, Malamani G, Mugellini A. Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive post-menopausal women. Am J Hypertens 2001 14 921-926
12. Fogari R, Mugellini A, Zoppi A, Corradi L, Preti P, Lazzari P, Derosa G. Losartan and perindopril effects on plasma fibrinogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetics. Am J Hypertens 2002 15 316-320
13. Fogari R, Preti P, Lazzari P, Corradi L, Zoppi A, Fogari E, Mugellini A. Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients. Eur J Clin Pharmacol 2003 59 271-275 (Pubitemid 37100344)
14. Paterna S, Di Garbo V, Avellone G, Di Pasquale P, Cacia A, Tuttolomondo A, Follone G, Cardinale A, Maniscalchi T, Licata G. Effects of losartan and delapril on the fibrinolytic system in patients with mild to moderate hypertension. Clin Drug Invest 2003 23 717-724 (Pubitemid 37373793)
15. Blood Pressure Lowering Treatment Trialist's Collaboration. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007 25 951-958
16. Lottermoser K, Hertfelder HH, Vetter H, Dusing R. Fibrinolytic function in diuretic induced volume depletion. Am J Hypertens 2000 13 359-363
17. Erdem Y, Usalan C, Haznedaroglu IC, Altun B, Arici M, Yasavul U, Turgan C, Calar S. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in system hypertension. Am J Hypertens 1999 11 1071-1076
18. Matsumoto T, Minai K, Horie H, Ohira N, Takashima H, Tarutani Y, Yasuda Y, Ozawa T, Matsuo S, Kinoshita M, Horie M. Angiotensin converting enzyme inhibition but not angiotensin II type 1 receptor antagonism augments coronary release of tissue plasminogen activator in hypertensive patients. J Am Coll Cardiol 2003 41 1373-1379
19. Skurk T, Lee YM, Nicuta-Rolfs TO, Haastert B, Wirth A, Hauner H. Effect of the angiotensin II receptor blocker candesartan on fibrinolysis in patients with mild hypertension. Diabetes Obes Metab 2004 6 56-62
20. Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 1995 96 2515-2520
21. Brown NJ, Gainer JV, Stein CM, Vaughan DE. Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension 1999 33 1431-1435
22. Frampton JE, Curran MP. Aliskiren. A review of its use in the management of hypertension. Drugs 2007 67 1767-1792
23. Gradman AH, Pinto R, Kad R. Current concepts: renin inhibition in the treatment of hypertension. Curr Opin Pharmacol 2008 8 120-126
24. Rashid H. Direct renin inhibition: an evaluation of the safety and tolerability of aliskiren. Curr Med Res Opin 2008 24 2627-2637
25. De Fronzo RA, Tobin JA, Andres B. Glucose clamp technique, a method for quantifying insulin secretion and resistance. Am J Physiol 1979 237 214-223
26. Grundy SM, Cleeman JI, Daniels SR, Donato DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F, American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005 112 2735-2752 (Pubitemid 41532612)
27. Verheijen JH, Chang GTC, Kluff C. Evidence for the occurrence of a fast acting inhibitor of tissue-type plasminogen activator in plasma. Thromb Haemost 1984 51 392-395
28. Velthuis-te Wierik EJ, Meijer P, Kluft C, Van der Berg H. Beneficial effect of a moderately energy-restricted diet on fibrinolytic factors in non obese men. Metabolism 1995 44 1548-1552
29. Mertens I, Van Gaal LF. Obesity, haemostasis and the fibrinolytic system. Obes Rev 2002 3 85-101
30. Brown NJ, Kumar S, Painter CA, Vaughan DE. Ace-inhibition versus angiotensin type I receptor antagonism. Differential effects on PAI-1 over time. Hypertension 2002 40 859-865
31. Vague P, Juan-Vague I, Alessi MC, Badier C, Valadier J. Metformin decreases the high plasminogen activator inhibitor capacity, plasma insulin and triglycerides levels in non diabetic obese subjects. Thromb Haemost 1987 57 326-328
32. Brown NJ, Agirbasli MA, Vaughan DE. Comparative effect of angiotensin converting enzyme inhibition and angiotensin II type I receptor antagonism on plasma fibrinolytic balance in humans. Hypertension 1999 34 285-290
33. Alessi MC, Juhan-Vague I, Declerck PJ, Collen D. Molecular forms of plasminogen activator 1 (PAI-1) and tissue plasminogen activator (tPA) in human plasma. Thromb Res 1991 62 275-285